Abstract #3756

Resting-state fMRI fails to detect disease progression in a multicenter randomized clinical trial of Alzheimer's disease

Coimbra Alexandre¹, Farshid Faraji¹, Alexander de Crespigny¹, Lee Honigberg¹, Robert Paul¹, and David Clayton¹

¹Research and Early Development, Genentech, South San Francisco, CA, United States

RS-fMRI was implemented in two multicenter clinical trials of a novel therapeutic for AD. Although data of good quality were acquired, none of three functional connectivity metrics (FCMs) showed significant progression associated with disease in placebo-treated patients: changes in connectivity in this mild-to-moderate AD population were less than the measurement precision. Significant cognitive decline and brain atrophy were observed. Test-retest precision was similar to other single-center studies. Operational and acquisition improvements could increase data quality (though difficult in multicenter trials), but more sensitive analysis will be needed for RS-fMRI to be a useful tool for the development of AD therapeutics.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.